title: A licence to cure.
authors.affiliation: Nuffield Department of Primary Care Health Sciences, Oxford OX2 6GG, UK jeffrey.aronson@phc.ox.ac.uk.
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Aronson
authors.affiliation: West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.
authors.forename: Robin E
authors.initials: RE
authors.lastname: Ferner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D008004:Licensure / Q000191:economics / Q000331:legislation & jurisprudence*; D056687:Off-Label Use / Q000191:economics* / Q000331:legislation & jurisprudence; D000069579:Ranibizumab; D006113:United Kingdom; D057135:Wet Macular Degeneration / Q000188:drug therapy / Q000191:economics
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab